Following its participation in Singapore International Menopause Congress 2026 (SIMC), Besins Healthcare and its partner PharMed further reinforced its position as a key player in menopause care across Asia-Pacific. As a Gold Sponsor, our presence at this major regional congress was fully aligned with our ambition to lead in menopausal hormone therapy (MHT).
Organised by the Menopause Research Society Singapore (MRSS) and the International Menopause Society (IMS), the congress took place in a highly strategic context. With the recent release of Singapore’s Clinical Guidelines for the Management of the Menopause Transition (led by IPRAMHO), menopause is gaining strong recognition as a national healthcare priority — creating the right environment to drive our expertise forward.
Driving Scientific Leadership
At the congress, Besins Healthcare took an active role in shaping the scientific dialogue through a Lunch Symposium led by Dr. Premitha Damodaran: “Transdermal Hormone Therapy – Revisiting Safety and Efficacy.”
This session directly supported our positioning by highlighting the relevance of transdermal MHT, in line with evolving clinical expectations and guidelines.
Expanding Influence and Partnerships
SIMC 2026 enabled us to strengthen our footprint across the region:
Deepened engagement with Dr. Ang Seng Bin (President, MRSS) and key Singapore KOLs
Reinforced our portfolio as a reference in MHT
Connected with physicians from Singapore, Malaysia, Pakistan and beyond
Supported our distributors’ development across Asia
Continued our collaboration with Dr. Premitha Damodaran, a key advocate for our solutions
Moving Forward
With menopause now a growing strategic focus in Singapore and Asia as a whole, Besins Healthcare is well positioned to play a leading role - leveraging strong scientific engagement, trusted partnerships, and a clearly differentiated MHT portfolio.
